Targeted therapies: Further delineating bevacizumab's response spectrum

Affiliations

Comment

David A Reardon et al. Nat Rev Clin Oncol. 2014 May.

. 2014 May;11(5):243-4.

doi: 10.1038/nrclinonc.2014.61. Epub 2014 Apr 8.

¹ Department of Medical Oncology, Centre for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

No abstract available

Comment on

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. Gilbert MR, et al. N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573. N Engl J Med. 2014. PMID: 24552317 Free PMC article. Clinical Trial.
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Chinot OL, et al. N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345. N Engl J Med. 2014. PMID: 24552318 Clinical Trial.
Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Tewari KS, et al. N Engl J Med. 2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748. N Engl J Med. 2014. PMID: 24552320 Free PMC article. Clinical Trial.